{"DataElement":{"publicId":"7652925","version":"1","preferredName":"Pharmacogenomics Biomarker Domain Biomarker Name","preferredDefinition":"Text name of an individual biomarker used for analysis.","longName":"PB_PBMRKR_NAME","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7652923","version":"1","preferredName":"Pharmacogenomics Biomarker Domain Biomarker Name","preferredDefinition":"A special purpose domain and reference dataset that associates observed genetic mutations with medical conclusions (e.g. disease diagnosis, drug resistance)._A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention._The words or language units by which a thing is known.","longName":"7652921v1.0:2557775v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7652921","version":"1","preferredName":"Pharmacogenomics Biomarker Domain","preferredDefinition":"A special purpose domain and reference dataset that associates observed genetic mutations with medical conclusions (e.g. disease diagnosis, drug resistance).","longName":"C106552","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacogenomics Biomarker Domain","conceptCode":"C106552","definition":"A special purpose domain and reference dataset that associates observed genetic mutations with medical conclusions (e.g. disease diagnosis, drug resistance).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2027C3D-0760-0C1F-E053-4EBD850A9B52","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2557775","version":"1","preferredName":"Biomarker Name","preferredDefinition":"Objectively measurable phenotypic parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype, presence of biological substances) that characterize an organism's state of health or disease, likelihood of developing a disease, or response to a particular therapeutic intervention.:The words or language units by which a thing is known.","longName":"C16342:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"24FC3833-E8CE-26F9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-19","endDate":null,"createdBy":"UMLLOADER_GEWRKBCH","dateCreated":"2006-12-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2027C3D-076E-0C1F-E053-4EBD850A9B52","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"CARPIOJ","dateModified":"2021-08-30","changeDescription":"5/10/2021 - JKC curated for PEPN2011","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7652919","version":"1","preferredName":"Neoplasm Biomarker Name","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention._The words or language units by which a thing is known.","longName":"7652919v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Lactate Dehydrogenase","valueDescription":"Lactate Dehydrogenase","ValueMeaning":{"publicId":"3364697","version":"1","preferredName":"Lactate Dehydrogenase","longName":"3364697","preferredDefinition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactate Dehydrogenase","conceptCode":"C25184","definition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B74DD08D-744A-8407-E040-BB89AD436311","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-01-24","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2028704-DDE6-2AB6-E053-4EBD850ABC07","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","deletedIndicator":"No"},{"value":"Other, specify:","valueDescription":"Other Specify","ValueMeaning":{"publicId":"4188777","version":"1","preferredName":"Other Specify","longName":"4188777","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Be specific about something; define clearly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CC9DDB-CE4D-9879-E040-BB89AD430A03","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2028704-DDF1-2AB6-E053-4EBD850ABC07","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","deletedIndicator":"No"},{"value":"Beta-human chorionic gonadotropin","valueDescription":"Human Chorionic Gonadotropin Beta Subunit","ValueMeaning":{"publicId":"2633458","version":"1","preferredName":"Human Chorionic Gonadotropin Beta Subunit","longName":"2633458","preferredDefinition":"The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriogonadotropin Subunit Beta 3","conceptCode":"C17479","definition":"Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F09EB21-604F-288C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-04-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2028704-DE06-2AB6-E053-4EBD850ABC07","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","deletedIndicator":"No"},{"value":"Carcinoembryonic Antigen","valueDescription":"Carcinoembryonic Antigen","ValueMeaning":{"publicId":"5438713","version":"1","preferredName":"Carcinoembryonic Antigen","longName":"5438713","preferredDefinition":"A cancer-specific antigen associated with both tumors and the developing fetus. The main use of this antigen is as a tumor marker, especially with respect to intestinal cancers. Production of the antigen ceases shortly before birth, but may reappear in people who develop certain types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoembryonic Antigen","conceptCode":"C25159","definition":"A cancer-specific antigen associated with both tumors and the developing fetus. The main use of this antigen is as a tumor marker, especially with respect to intestinal cancers. Production of the antigen ceases shortly before birth, but may reappear in people who develop certain types of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B3E8004-06EE-AC1B-E050-BB89AD43171C","latestVersionIndicator":"Yes","beginDate":"2016-08-29","endDate":null,"createdBy":"DWARZEL","dateCreated":"2016-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2028704-DE1C-2AB6-E053-4EBD850ABC07","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","deletedIndicator":"No"},{"value":"Alpha-fetoprotein","valueDescription":"Alpha-Fetoprotein","ValueMeaning":{"publicId":"2633460","version":"1","preferredName":"Alpha-Fetoprotein","longName":"2633460","preferredDefinition":"Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Fetoprotein","conceptCode":"C16278","definition":"Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F09EB21-6076-288C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-04-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":"Updated definition to match current NCIt. mc 12.12.17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2028704-DE27-2AB6-E053-4EBD850ABC07","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435027","version":"1","preferredName":"Gene","preferredDefinition":"A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).","longName":"C16612","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB05-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7652918","version":"1","preferredName":"Neoplasm Biomarker Name","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.:The words or language units by which a thing is known.","longName":"C3262:C16342:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Biomarker","conceptCode":"C16342","definition":"A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2028704-DDB3-2AB6-E053-4EBD850ABC07","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"ONEDATA","dateModified":"2021-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C2028704-DDC4-2AB6-E053-4EBD850ABC07","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"CARPIOJ","dateModified":"2021-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the biomarker name?","type":"Preferred Question Text","description":"What is the biomarker name?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Biomarker Name:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C202CB1B-879A-1759-E053-4EBD850AAE76","latestVersionIndicator":"Yes","beginDate":"2021-05-10","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-05-10","modifiedBy":"CARPIOJ","dateModified":"2021-08-30","changeDescription":"5/10/2021 - Curated for PEPN2011.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}